# Eli Lilly reports promising lung cancer drug results — retained record

> Retained news record from news:seeking-alpha.

Canonical: https://highsignal.app/data/records/463870203adfc080

[← sources](https://highsignal.app/data)


source: [news](https://highsignal.app/data/news) (news:seeking-alpha)  published 2026-10-25 22:57 ingested 2026-10-26 02:57

[original source ↗](https://seekingalpha.com/news/4657011-eli-lilly-reports-promising-lung-cancer-drug-results?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news)

## retained text



```
The results strengthen Eli Lilly’s prospects to enter the targeted KRAS G12C-mutated lung cancer market, indicating potential for a new initial treatment where no targeted therapies are currently approved.

Olomorasib with Keytruda and chemotherapy achieved a 62% confirmed tumor response rate, with median responses lasting 14.5 months and median progression-free survival of 11.6 months.

The findings lack randomized comparison groups, making it premature to conclude olomorasib’s superiority over existing treatments until further Phase 3 randomized trial results are available.
```



document fetched 2026-10-26 02:57 · canonical https://seekingalpha.com/news/4657011-eli-lilly-reports-promising-lung-cancer-drug-results?feed_item_type=news